﻿{"id":12751,"date":"2026-11-19T18:21:11","date_gmt":"2026-11-19T12:51:11","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/ipcalab-share-price-today-2026-11-19\/"},"modified":"2026-11-19T18:21:13","modified_gmt":"2026-11-19T12:51:13","slug":"ipcalab-share-price-today-2026-11-19","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/ipcalab-share-price-today-2026-11-19\/","title":{"rendered":"Ipca Laboratories Share Price Today: Why IPCALAB Is Rising 0.32% | 19 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: IPCALAB<\/strong> \u00b7 19 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,860.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+0.32%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,890.50 \/ \u20b91,845.10<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,854.10<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>2.58 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>19 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Ipca Laboratories Ltd. (IPCALAB) edged up by 0.32% today, closing at \u20b91,860.00 compared to its previous close of \u20b91,854.10. The stock opened at \u20b91,862.20 and moved within a day&#x27;s range of \u20b91,845.10 and \u20b91,890.50, spending the session trading closer to its lower half before finding modest support.<\/li>\n<li>IPCA Laboratories Limited submitted its standalone and consolidated financial results for the second quarter and half year ended September 30, 2026, to the stock exchange. The company also hosted an analyst and investor conference call on the same day, with transcript outcomes published on November 6, 2026. These filings provide comprehensive visibility into the company&#x27;s quarterly revenue, margin performance, and operational expenditures.<\/li>\n<li>Trading volume was 0.88 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Ipca Laboratories share price rising on 19 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Ipca Laboratories Ltd. (IPCALAB) edged up by 0.32% today, closing at \u20b91,860.00 compared to its previous close of \u20b91,854.10. The stock opened at \u20b91,862.20 and moved within a day&#x27;s range of \u20b91,845.10 and \u20b91,890.50, spending the session trading closer to its lower half before finding modest support.<\/p>\n<p class=\"wt-copy\">In broader market context, the benchmark Nifty advanced by 1.14%, while the sector-specific Nifty Pharma index gained 0.61%. While the pharmaceutical sector witnessed positive momentum led by broader healthcare buying, Ipca Laboratories lagged behind both the broader index and its immediate sectoral benchmark, reflecting isolated price action rather than a strong sector-wide surge.<\/p>\n<p class=\"wt-copy\">The move occurs against the backdrop of the company&#x27;s financial disclosures for the quarter ended September 30, 2026, submitted to the exchanges on November 5, 2026, alongside subsequent investor conference call transcripts published on November 6, 2026. However, because these operational updates were released earlier in the month, they do not represent an immediate same-day catalyst for today&#x27;s modest price fluctuation. The current price action appears to be driven by general market positioning following recent weekly pullbacks rather than a fresh corporate announcement.<\/p>\n<p class=\"wt-copy\">2.58 lakh shares traded by 19 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 2.94 lakh shares (0.88 times). The five-day average daily volume was 2.25 lakh shares. Separately, the NSE report for 19 November 2026 showed 1.77 lakh shares delivered, representing 68.68% of that day\u2019s traded volume. The same report recorded 43,689 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Stock-specific narrow range movement with low volume participation<\/strong><\/p>\n<p class=\"wt-copy\">No single confirmed trigger links directly to today&#x27;s 0.32% gain. The stock traded in a narrow band on below-average 20-day volume (0.88 ratio), lagging the broader Nifty and Nifty Pharma indices. The move reflects routine cash market consolidation following recent weekly pullbacks.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">September 2026 Financial Results<\/div>\n<div class=\"wt-card-date\">5 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">IPCA Laboratories Limited submitted its standalone and consolidated financial results for the second quarter and half year ended September 30, 2026, to the stock exchange. The company also hosted an analyst and investor conference call on the same day, with transcript outcomes published on November 6, 2026. These filings provide comprehensive visibility into the company&#x27;s quarterly revenue, margin performance, and operational expenditures.<\/p>\n<p class=\"wt-copy\">Quarterly earnings updates directly influence institutional valuations and fundamental expectations for the pharmaceutical manufacturer.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Strategic Licensing Agreement for Biologics Platform<\/div>\n<div class=\"wt-card-date\">12 June 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company entered into a licensing agreement granting Ipca access to BRL&#x27;s proprietary high-concentration subcutaneous biologics delivery platform. The partnership targets the development and commercialization of multiple monoclonal antibody products focusing on oncology and inflammatory diseases. This collaboration expands Ipca&#x27;s technological capabilities into complex biologic formulations.<\/p>\n<p class=\"wt-copy\">This agreement strengthens the company&#x27;s long-term pipeline in chronic therapies and specialty biologics.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">5 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">12 June 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated Jun 12, 2026, titled &quot;Licensing agreement granting Ipca access to BRL&#x27;s proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialization of multiple monoclonal antibody products targeting oncology and inflammatory diseases. &quot;.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">44.72%<\/div>\n<div class=\"wt-note\">44.72% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">11.53%<\/div>\n<div class=\"wt-note\">10.73% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">48.12%<\/div>\n<div class=\"wt-note\">48.10% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>MANISH KUMAR JAIN<\/strong><span class=\"wt-note\">Insider \/ disclosed person<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Sell<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>3,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>16 February 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 31.07% on 30 September 2026. This compares with 31.15% on 30 June 2026, a change of -0.08 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 31 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.41 crore shares \u00b7 9.51%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">KOTAK MAHINDRA MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.61 crore shares \u00b7 6.34%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">DSP MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.05 crore shares \u00b7 4.12%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">20 May 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b92,200.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Ruchit Jain of Motilal Oswal suggested Ipca Laboratories shares as a short-term buy based on technical setup and momentum indicators.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Delivery percentage trends relative to the 68.68% recorded on November 19, 2026<\/li>\n<li>Trading volume recovery toward or above the 20-day average volume baseline<\/li>\n<li>Performance relative to the Nifty Pharma sector benchmark<\/li>\n<li>Execution progress on the high-concentration subcutaneous biologics delivery platform<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/ipcalab-share-price-today-2026-11-06\/\">Ipca Laboratories Share Price Today: Why IPCALAB Is Falling 0.40% | 6 November 2026 \u2014 6 November 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/ipcalab-share-price-today-2026-11-05\/\">Ipca Laboratories Share Price Today: Why IPCALAB Is Falling 1.14% | 5 November 2026 \u2014 5 November 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/ipcalab-share-price-today-2026-10-30\/\">Ipca Laboratories Share Price Today: Why IPCALAB Is Rising 0.08% | 30 October 2026 \u2014 30 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/ipcalab\/\">More Ipca Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Ipca Laboratories company news?<\/h3>\n<p class=\"wt-copy\">IPCA Laboratories Limited submitted its standalone and consolidated financial results for the second quarter and half year ended September 30, 2026, to the stock exchange. The company also hosted an analyst and investor conference call on the same day, with transcript outcomes published on November 6, 2026. These filings provide comprehensive visibility into the company&#x27;s quarterly revenue, margin performance, and operational expenditures.<\/p>\n<h3>How strong was Ipca Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">2.58 lakh shares traded, 0.88 times the 20-day average daily volume. The price and volume data are dated 19 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/ipcalab-share-price-today-2026-11-19\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/ipcalab-share-price-today-2026-11-19\/\"}, \"headline\": \"Ipca Laboratories Share Price Today: Why IPCALAB Is Rising 0.32% | 19 November 2026\", \"description\": \"Ipca Laboratories share price rose 0.32% to \u20b91,860.00 today. See why IPCALAB is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-11-19T18:21:01.072187+05:30\", \"dateModified\": \"2026-11-19T18:21:01.072187+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Ipca Laboratories\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"IPCALAB\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/ipcalab-company-news-2026-11-19.jpg\"]}]}<\/script><!-- wt-article-record:{\"recent_news\":[{\"summary\":\"IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"05-Nov-2026 13:42:48\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.in\/corporate\/IPCALAB_05112026134131_IpcaResultsandPressRelease.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"13-Aug-2026 13:35:54\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.in\/corporate\/IPCALAB_13082026133427_IpcaResultsQ1FY27.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"29-May-2026 13:51:38\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.in\/corporate\/IPCALAB_29052026135015_IpcaQ4FY26Results.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated Jun 12, 2026, titled \\\"Licensing agreement granting Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform for the development and commercialization of multiple monoclonal antibody products targeting oncology and inflammatory diseases. \\\".\",\"category\":\"Press Release\",\"date\":\"12-Jun-2026 17:31:31\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.in\/corporate\/IPCALAB_12062026173120_IpcaPressReleaseBhami12062026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4}],\"insider_activity\":[{\"person\":\"MANISH KUMAR JAIN\",\"category\":\"Insider \/ disclosed person\",\"type\":\"Sell\",\"quantity\":\"3000\",\"post_holding\":\"20266\",\"date\":\"16-Feb-2026\",\"mode\":\"Market Sale\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":44.72,\"public_pct\":55.28,\"fii_pct\":11.53,\"dii_pct\":36.59,\"mf_pct\":31.07,\"institutional_pct\":48.12,\"noninst_pct\":7.15,\"mf_scheme_count\":31,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC MUTUAL FUND\",\"shares\":24124917,\"pct\":9.51},{\"name\":\"KOTAK MAHINDRA MUTUAL FUND\",\"shares\":16087048,\"pct\":6.34},{\"name\":\"DSP MUTUAL FUND\",\"shares\":10451645,\"pct\":4.12},{\"name\":\"NIPPON INDIA MUTUAL FUND\",\"shares\":6906226,\"pct\":2.72},{\"name\":\"AXIS MUTUAL FUND\",\"shares\":5186894,\"pct\":2.04}],\"period\":\"30-SEP-2026\",\"submission_date\":\"13-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.in\/corporate\/xbrl\/SHP_1736726_13102026011741_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":44.72,\"previous_fii_pct\":10.73,\"previous_dii_pct\":37.37,\"previous_mf_pct\":31.15,\"previous_institutional_pct\":48.1,\"previous_mf_scheme_count\":33,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Buy\",\"target\":\"2200\",\"view_summary\":\"Ruchit Jain of Motilal Oswal suggests Siemens Energy, Ipca Lab shares to buy for the short term Livemint\",\"headline\":\"Ruchit Jain of Motilal Oswal suggests Siemens Energy, Ipca Lab shares to buy for the short term\",\"published\":\"2026-05-20T07:00:00+00:00\",\"source\":\"Livemint\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ipca Laboratories share price rose 0.32% to \u20b91,860.00 today. See why IPCALAB is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":12750,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Ipca Laboratories Share Price Today: Why IPCALAB Is Rising 0.32% | 19 November 2026","_witty_meta_description":"Ipca Laboratories share price rose 0.32% to \u20b91,860.00 today. See why IPCALAB is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Ipca Laboratories share price today","_witty_reason_label":"Stock-specific narrow range movement with low volume participation","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[384],"class_list":["post-12751","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-ipcalab"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/12751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=12751"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/12751\/revisions"}],"predecessor-version":[{"id":12752,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/12751\/revisions\/12752"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/12750"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=12751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=12751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=12751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}